The estimated Net Worth of Thomas P. O'neil is at least $438 Тысяча dollars as of 1 September 2020. Mr neil owns over 750 units of Satsuma Pharmaceuticals stock worth over $825 and over the last 8 years he sold STSA stock worth over $0. In addition, he makes $436,960 as Chief Financial Officer at Satsuma Pharmaceuticals.
Mr has made over 8 trades of the Satsuma Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 750 units of STSA stock worth $3,420 on 1 September 2020.
The largest trade he's ever made was exercising 8,000 units of Satsuma Pharmaceuticals stock on 18 December 2017 worth over $21,520. On average, Mr trades about 1,124 units every 66 days since 2016. As of 1 September 2020 he still owns at least 750 units of Satsuma Pharmaceuticals stock.
You can see the complete history of Mr neil stock trades at the bottom of the page.
Thomas P. O'Neil is the Chief Financial Officer at Satsuma Pharmaceuticals.
As the Chief Financial Officer of Satsuma Pharmaceuticals, the total compensation of Mr Neil at Satsuma Pharmaceuticals is $436,960. There are 5 executives at Satsuma Pharmaceuticals getting paid more, with John Kollins having the highest compensation of $1,368,100.
Mr Neil is 56, he's been the Chief Financial Officer of Satsuma Pharmaceuticals since . There are 8 older and 6 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... и Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: